Phase 2 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a suspected or confirmed diagnosis of glioblastoma (a type of brain tumor) — this applies to groups 1, 2, and 3 in the trial
- People who have a suspected or confirmed diagnosis of vestibular schwannoma (a non-cancerous tumor near the ear and brain) — this applies to group 4 in the trial
- People who are already planning to have surgery to remove their tumor as part of their normal medical care, including those who have previously had chemotherapy, radiation, or a diagnostic biopsy
- People who are 18 years of age or older
- People who are willing and able to give informed consent, attend all scheduled visits, and follow all study requirements — or who have a designated advocate able to do this on their behalf
Who may not be able to join:
- People who have taken part in another clinical trial and received an experimental drug within the 30 days before the first dose of the study drug
- People who have had a heart attack, stroke, uncontrolled heart failure, significant liver disease, or unstable chest pain within the 6 months before enrolling
- People who have had a serious reaction to a type of medication called a monoclonal antibody in the past
- People who are currently pregnant or breastfeeding
- People whose heart electrical activity test (ECG) shows a specific abnormality called QTc prolongation (over 440 milliseconds in males or over 460 milliseconds in females)
- People whose blood test results fall outside the required ranges, including low platelet counts, abnormal thyroid hormone levels, low levels of magnesium, potassium, or calcium, or high levels of a kidney marker called creatinine (confirm specific values with trial site)
- People who are currently taking certain heart rhythm medications known as Class IA (such as quinidine or procainamide) or Class III (such as amiodarone, dofetilide, or sotalol) antiarrhythmic drugs
- People who have a history of lung inflammation (interstitial pneumonitis) or lung scarring (pulmonary fibrosis)
- People whom the lead trial doctor does not consider suitable candidates for the best possible surgical removal of their tumor, based on the tumor's location or other factors
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lindsay Moore, MD, Stanford University
Phone: (650) 723-5281
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of grade 2 or higher adverse events which have been determined to be clinically significant and definitely, probably, or possibly related to the study treatment, graded according to Common Terminology Criteria for Adverse Effects (CTCAE) v. 4.0
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.